Ariadne Genomics, Inc. provides pathway analysis tools and semantic technologies for pharmaceutical and life science researchers. The company offers solutions for life science, drug discovery, and development applications, including data products, knowledge extraction and visualization software, knowledge reports, and informatics staffing. It provides Pathway Studio software that offers a desktop graphical user interface with capability to create and draw protein interaction networks and pathways using the data based upon information from the literature. The company also offers ResNet Databases, such as ResNet Mammalian, a protein-centric knowledgebase for the study of human, mouse, and rat biology; ResNet Plant, a protein-centric knowledgebase for the study of plants; ChemEffect, a compound-centric database for the study of the effects of drugs, biologics, and environmental chemicals on biological systems; DiseaseFx, a disease-centric database for the study of the molecular cause and effects of disease on cellular processes; and Prolexys HyNet, a protein interaction database. It offers its software for use in various areas of research, such as analysis of proteomics data, biomarkers, disease mechanisms, drug and target discovery, human genetics, microarray gene expression data, model organisms, pathway analysis, text mining, and toxicology and toxicogenomics. Its Pathway Studio software product is used by pharmaceutical, agriculture, and academic institutions to provide molecular analyses of disease areas and disease progression. It offers its products through distributors in Europe, Australia, South Korea, Japan, Singapore, Taiwan, and internationally. The company was founded in 2002 and is based in Rockville, Maryland with sales offices in Massachusetts, Colorado, and California; and Europe. As of December 8, 2011, Ariadne Genomics, Inc. operates as a subsidiary of Elsevier B.V.
